Vivani Medical, Inc. filings document a clinical-stage company with Nasdaq-listed common stock and development activities in NanoPortal™ drug implants and Cortigent neurostimulation devices. Recent Form 8-K reports cover operating results, Regulation FD corporate presentations, material definitive agreements, registered direct offerings and private placements that affect common-stock capital structure.
Proxy materials disclose board elections, executive compensation, equity awards, shareholder voting procedures and other governance matters. The filing record also includes formal disclosures tied to clinical and business updates for Vivani’s semaglutide implant candidates and corporate-structure matters involving its wholly owned Cortigent subsidiary, including the Orion® Visual Cortical Prosthesis System.
Vivani Medical, Inc. reported equity compensation for Chief Operations Officer Le Truc consisting of a stock option for 160,000 shares of common stock at an exercise price of $1.31 per share, expiring in 2036, and 80,000 performance-based RSUs tied to achieving a $3.15 share-price hurdle over a four-year term. The option has a 10-year term and vests 25% after one year, then monthly over 36 months, while the RSUs vest in three tranches based on this market condition and time-based anniversaries, subject to continued service.
Vivani Medical, Inc. granted Chief Executive Officer Adam Mendelsohn 200,000 stock options and 100,000 performance-based RSUs on July 28, 2026. The options have a $1.31 exercise price, a 10-year term, and vest 25% after one year then monthly for 36 months. Each RSU equals one share and vests in three stages tied to Vivani's stock trading at or above $3.15 for three consecutive trading days, with additional tranches one and two years after that date; the RSUs expire if this price condition is not met within four years and all vesting requires continued service.
BRADBURY DANIEL reported acquisition or exercise transactions in this Form 4 filing.
Vivani Medical, Inc. reported that director Daniel Bradbury received a grant of 7,965 non-qualified stock options to buy common stock at 1.3000 per share. The options have a 10-year term, expire on July 26, 2026, and vest quarterly through December 31, 2026, subject to his continued service. The award, held directly, was issued under the non-employee director compensation policy in lieu of $8,000 in cash retainer fees for increased committee service, leaving him with 7,965 options reported in this grant.
Vivani Medical, Inc. director and 10% owner Gregg Williams reported buying 793,650 shares of common stock in a private sale at $1.26 per share, as disclosed in an August 11, 2025 Share Purchase Agreement. The gross proceeds for this private sale transaction were $999,999.00. Following the purchase, he beneficially owns 41,711,936 shares directly and through several trusts and LLCs, and has voting and dispositive power over all of these shares.
Vivani Medical, Inc. furnished an investor slide presentation used at the Emerging Growth Conference in New York on July 15, 2026 at 4:10 p.m. Eastern Time. The presentation, delivered by CEO Dr. Adam Mendelsohn, includes an update that the company’s first dosing of SLIM-1 is expected in August 2026.
The information in the presentation is provided under Regulation FD, is not deemed filed or subject to liability under Section 18 of the Exchange Act, and is not incorporated by reference into other securities law filings unless expressly referenced.
Vivani Medical, Inc. reports that its wholly owned subsidiary Cortigent, Inc. has signed an Agreement and Plan of Merger with ClearOne, Inc., under which Cortigent will merge into a ClearOne subsidiary and become a wholly owned ClearOne unit. Vivani’s Cortigent equity will be converted at closing into 12,500,000 shares of ClearOne common stock, while ClearOne must complete a concurrent Form S-1 financing of $10,000,000 to $15,000,000 through 2,500,000 to 5,000,000 units, each with one share and a warrant exercisable at $10.00. The merger is subject to stockholder approvals, Nasdaq listing conditions, completion of the financing and other customary closing conditions, and includes a breakup-fee mechanism capped at $250,000. Vivani also announces a separate non-exclusive agreement with Novo Nordisk, allowing Novo Nordisk to internally evaluate Vivani’s NPM-139 semaglutide NanoPortal implant for chronic weight management, alongside plans to start a Phase 1 first-in-human study with Wegovy injections as an active comparator in mid-2026.
Vivani Medical held its 2026 annual stockholder meeting and approved an amended 2022 Omnibus Incentive Plan that increases the common shares reserved for equity awards by 11,000,000, from 10,033,333 to 21,033,333 shares. Stockholders also re-elected six directors, approved executive compensation on a non-binding advisory basis, and ratified BPM LLP as auditor for the year ending December 31, 2026. The meeting reached a quorum with 62,071,530 of 86,235,104 common shares represented in person or by proxy.
Separately, Vivani received approval from Bellberry, a human research ethics committee in Australia, to initiate SLIM-1, a Phase 1 clinical trial of NPM-139, a semaglutide implant for obesity and chronic weight management. SLIM-1 is designed as an open-label, randomized, active comparator-controlled trial evaluating low-dose NPM-139 versus Wegovy 0.25 mg/week over four weeks in obese or overweight subjects, with 10 participants per group, focusing on safety, tolerability, and pharmacokinetics while also measuring weight loss.
Vivani Medical director August J. Moretti received a grant of non-qualified stock options covering 36,000 shares of common stock at an exercise price of $1.22 per share. The award was made under Vivani’s Non-Employee Director Compensation Policy and vests in monthly installments over three years, with the options expiring on June 23, 2036. This is a compensation-related equity grant rather than an open-market purchase or sale.
Vivani Medical, Inc. filed an initial Form 3 for director August J. Moretti. The data provided shows no reported purchases, sales, gifts, tax withholdings, restructurings, or derivative exercises, and no derivative positions listed in the derivative summary.
Vivani Medical, Inc. director and 10% owner Gregg Williams reported receiving a grant of non-qualified stock options for 36,516 shares of common stock at an exercise price of $1.22 per share. This compensation award was made under the company’s Non-Employee Director Compensation Policy.
The options vest in full on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders, subject to Mr. Williams’ continued service through that date, and are scheduled to expire on June 23, 2036.